Breadcrumb

Entity Print

Fabio Ciceri
ALWP Chair
Italy

Major achievements

The activity of the ALWP continues to increase thanks to the great contribution of the ALWP members and collaborators and the continuous efforts of the ALWP staff. Study proposals are presented with relevant questions for investigating factors associated with patients outcomes. All these achievements are possible with the continuous and voluntary work of distinguished colleagues, and I thank all of them

for it.

One of the main topics of the ALWP is the data collection on next-generation sequencing (NGS) data and use of novel drugs, with the aim to improve the quality of the registry and the scientific output of the publications to the benefit of the patient's care.

The number of transplants for patients with acute leukaemia is constantly growing, with increase in the HCT indications, as well the age of the patients and diseases. The role of age and donor kinship has been analysed in different transplant settings to implement the algorithm of donor selection for patients in need of HCT.

I am very grateful for your tireless efforts in sending such complex data, which will definitely lead to the generation of new knowledge to further advance the management of acute leukaemia.

Principal research studies

COLLECTION OF NEXT-GENERATION SEQUENCING (NGS) DATA AND USE OF NOVEL DRUGS IN ACUTE LEUKEMIA PATIENTS
Study type
Retrospective Studies
Diseases
Acute Lymphatic Leukaemia (ALL)
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment

Principal investigator
Prof M. Mohty
Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)

Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic
Principal investigator
Ali Bazarbachi
Long term outcomes and relative mortality in survivors of allogeneic hematopoietic cell transplantation in acute myeloid leukemia: an analysis from the ALWP of the EBMT
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic
Principal investigator
Vivek Patel
PTCY MMUD vs Haplo in active disease for AML
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic - Haploidentical
Principal investigator
Frédéric Baron
Outcome after allogeneic SCT for MLL-PTD AML
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment

Allogeneic
Principal investigator
Marta Pratcorona

Key publications

2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Ryszard Swoboda
Journal
Bone Marrow Transplant.
2023
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Alexandros Spyridonidis
Journal
Bone Marrow Transplant.
2023
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Jesús Duque-Afonso
Journal
Bone Marrow Transplant.
2023

Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Giorgia Battipaglia

Journal

Transplant Cell Ther.

2023

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Arnon Nagler

Journal

Bone Marrow Transplant.

See the full list of the ALWP 2023 publications



	2021	2022	2023
Oral presentations	10	14	**23**
Poster presentations	8	22	**22**
Educational events	1	4	**3**

[Event]

49th Annual Meeting of the EBMT

Apr 23, 2023 - Apr 26, 2023 / Paris, France
Discover more

- 7th IPC Symposium Advances in Transplant and Cellular Immunotherapy in Older Patients - 23-25 June 2023 in Marseille, France

VISIT THE ALWP WEBPAGE